Edition:
United Kingdom

TESARO Inc (TSRO.OQ)

TSRO.OQ on NASDAQ Stock Exchange Global Select Market

37.69USD
21 Sep 2018
Change (% chg)

-- (--)
Prev Close
$37.69
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
553,400
52-wk High
$129.47
52-wk Low
$25.62

Select another date:

Tue, Jun 5 2018

BRIEF-Tesaro Announces Collaboration To Evaluate Zejula In Combination With Anti-PD-L1 Cancer Immunotherapy, MEK Inhibitor In Platinum-Sensitive Ovarian Cancer

* TESARO ANNOUNCES COLLABORATION TO EVALUATE ZEJULA® IN COMBINATION WITH ANTI-PD-L1 CANCER IMMUNOTHERAPY AND MEK INHIBITOR IN PLATINUM-SENSITIVE OVARIAN CANCER

BRIEF-Tesaro Reports Q1 Loss Per Share Of $2.98

* Q1 EARNINGS PER SHARE VIEW $-2.69 -- THOMSON REUTERS I/B/E/S

BRIEF-Tesaro Announces Positive Top-Line Results From Quadra Trial Of Zejula

* TESARO ANNOUNCES POSITIVE TOP-LINE RESULTS FROM QUADRA TRIAL OF ZEJULA

BRIEF-Tesaro Summarizes TSR-042 Clinical Data Presented At AACR

* TESARO INC - EXPECT TO COMPLETE ENROLLMENT IN MSI-H ENDOMETRIAL COHORT OF GARNET TRIAL BY END OF YEAR Source text for Eikon: Further company coverage:

BRIEF-Tesaro And Medison Enter Into Exclusive Distribution Agreement To Commercialize Zejula In Israel

* TESARO AND MEDISON ENTER INTO EXCLUSIVE DISTRIBUTION AGREEMENT TO COMMERCIALIZE ZEJULA® IN ISRAEL

BRIEF-Tesaro Says TOPACIO Data Demonstrates Compelling Clinical Activity Of Zejula In Patients With Type Of Ovarian Cancer

* DATA FROM TOPACIO TRIAL REPORTED AT SGO DEMONSTRATES COMPELLING CLINICAL ACTIVITY OF ZEJULA IN COMBINATION WITH AN ANTI-PD-1 ANTIBODY IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY OVARIAN CANCER

Select another date: